Last reviewed · How we verify
glucose-dependent insulinotropic peptide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
glucose-dependent insulinotropic peptide (glucose-dependent insulinotropic peptide) — Steno Diabetes Center Copenhagen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| glucose-dependent insulinotropic peptide TARGET | glucose-dependent insulinotropic peptide | Steno Diabetes Center Copenhagen | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- glucose-dependent insulinotropic peptide CI watch — RSS
- glucose-dependent insulinotropic peptide CI watch — Atom
- glucose-dependent insulinotropic peptide CI watch — JSON
- glucose-dependent insulinotropic peptide alone — RSS
Cite this brief
Drug Landscape (2026). glucose-dependent insulinotropic peptide — Competitive Intelligence Brief. https://druglandscape.com/ci/glucose-dependent-insulinotropic-peptide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab